Advertisement

Topics

Formycon AG FYB Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

17:02 EST 20 Nov 2017 | BioPortfolio Reports

Summary


Formycon AG Formycon formerly Nanohale AG is a biopharmaceutical company that develops biosimilar drugs. The company offers biopharmaceutical imitation products for global recovery. It develops FYB201, used in the treatment of ophthalmology disorders. Formycon has facilities for protein characterization, formulation development, drug delivery technologies, pharmaceutical process development, drug production for preclinical studies and analytical services. The company also provides monoclonal antibodies for the treatment of cancer. It provides external preclinical and clinical testing services to biotechnology and pharmaceutical companies. Formycon is headquartered in Munich, Germany.


Formycon AG Key Recent Developments


Nov 16,2016: Formycon Makes Good Progress in First Nine Months of 2016

Sep 20,2016: Formycon Reports First Half 2016 Financial and Operating Results

Jul 07,2016: Formycon Expands Board and Appoints Pharma Top Manager Dr. Stefan Glombitza as Chief Operating Officer

Apr 20,2016: Formycon ends 2015 fiscal year with successful results

Feb 01,2016: Formycon appoints biotech expert Professor Johannes Buchner to the Advisory Board


This comprehensive SWOT profile of Formycon AG provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Formycon AG including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends.


The profile contains critical company information including*,


Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Note*: Some sections may be missing if data is unavailable for the company.


Key benefits of buying this profile include,


You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.


Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.


Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.


Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.


Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Original Article: Formycon AG FYB Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

NEXT ARTICLE

More From BioPortfolio on "Formycon AG FYB Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...